Arvinas (ARVN) reports positive Phase 1 ARV-102 data in Parkinson’s disease

Rhea-AI Filing Summary

Arvinas, Inc. reported positive Phase 1 data for ARV-102, an investigational oral PROTAC degrader of LRRK2 in patients with Parkinson’s disease. Multiple daily doses of 20 mg, 40 mg, and 80 mg for 28 days were well tolerated, with only mild adverse events, no serious adverse events, no discontinuations, and no deaths, and no significant changes in lung function.

ARV-102 showed brain penetration with cerebrospinal fluid exposure increasing in a dose-dependent manner and a mean plasma half-life of 68 hours. It achieved approximately 50% or greater LRRK2 reduction in cerebrospinal fluid at all doses by day 14, maintained through day 28, and reduced endolysosomal and neuroinflammatory biomarkers such as CD68 and GPNMB.

Based on these results, Arvinas plans to continue developing ARV-102 in neurodegenerative diseases linked to LRRK2 and endolysosomal dysfunction and, pending regulatory feedback, intends to start a Phase 1b trial in progressive supranuclear palsy in the second quarter of 2026, with potential initiation of a registrational trial in late 2026.

Positive

• Robust target engagement and biomarker effects: ARV-102 achieved approximately 50% or greater LRRK2 reduction in cerebrospinal fluid at all tested doses by day 14, maintained through day 28, with concurrent reductions in endolysosomal and neuroinflammatory biomarkers such as CD68 and GPNMB.
• Favorable Phase 1 safety profile: Multiple daily oral doses of 20 mg, 40 mg, and 80 mg for 28 days in Parkinson’s patients were well tolerated, with only mild adverse events, no serious adverse events, no discontinuations, no deaths, and no significant lung or respiratory changes.
• Clear development path outlined: Based on the data, Arvinas plans to continue ARV-102 development in LRRK2-related neurodegenerative diseases and, pending regulatory feedback, intends to initiate a Phase 1b trial in progressive supranuclear palsy in Q2 2026, with potential for a registrational trial in late 2026.

Negative

• None.

Insights

Biopharma clinical development analyst

Early ARV-102 data show strong target engagement with clean safety, supporting advancement into larger neurodegeneration trials.

The report describes Phase 1 multiple-ascending-dose data for ARV-102 in Parkinson’s disease. Once-daily oral doses of 20–80 mg over 28 days were well tolerated, with only mild adverse events, no serious events, no discontinuations, and no deaths, and no significant lung function changes.

Pharmacokinetic data show dose-dependent exposure, including in cerebrospinal fluid, and a mean plasma half-life of 68 hours. Pharmacodynamically, ARV-102 achieved approximately 50% or greater LRRK2 reduction in cerebrospinal fluid at all doses by day 14, maintained through day 28, and reduced biomarkers such as CD68 and GPNMB, aligning with prior healthy volunteer data.

The company plans to advance ARV-102 into a Phase 1b trial in progressive supranuclear palsy in Q2 2026, with a potential registrational trial in late 2026, while continuing to evaluate options in Parkinson’s disease. These steps move ARV-102 toward larger, disease-focused studies, though clinical efficacy remains to be demonstrated.

0001655759FALSE00016557592026-03-182026-03-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________

FORM 8-K

__________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 18, 2026

__________________

Arvinas, Inc.

(Exact name of registrant as specified in its charter)

__________________

Delaware			001-38672			47-2566120
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

5 Science Park 395 Winchester Ave. New Haven, Connecticut			06511
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (203) 535-1456

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

__________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

ARVN

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01 Regulation FD Disclosure

On March 18, 2026, Arvinas, Inc. (the "Company") issued a press release announcing positive Phase 1 clinical trial data for ARV-102, an investigational, orally bioavailable PROteolysis TArgeting Chimera ("PROTAC") designed to cross the blood-brain barrier and specifically target and degrade leucine-rich repeat kinase 2 ("LRRK2"), showing greater than 50% LRRK2 degradation in the cerebrospinal fluid ("CSF") of patients with Parkinson’s disease treated for 28 days. Data from the single-center, randomized, double-blind, placebo-controlled, multiple dose ("MD") cohort of the Phase 1 clinical trial in patients with Parkinson's disease were shared in an oral presentation at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders ("AD/PD™ 2026") in Copenhagen, Denmark.

The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On March 18, 2026, the Company issued a press release announcing positive Phase 1 clinical trial data for ARV-102, an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and specifically target and degrade LRRK, showing greater than 50% LRRK2 degradation in the CSF of patients with Parkinson’s disease treated for 28 days.

The ARV-102 Phase 1 clinical trial is designed to assess the safety, pharmacokinetics, and pharmacodynamics of orally administered ARV-102 in patients with Parkinson's disease. Data from the single-center, randomized, double-blind, placebo-controlled, MD cohort of the Phase 1 clinical trial in patients with Parkinson's disease were shared in an oral presentation at AD/PD™ 2026 in Copenhagen, Denmark. In the MD cohort, patients were randomized to either placebo or multiple oral doses of ARV-102 (20 mg, 40 mg, or 80 mg) for 28 days with follow-up at day 42.

Data presented from the clinical trial included the following:

Safety Profile

•Multiple oral doses of ARV-102 (20 mg, 40 mg, or 80 mg once daily for 28 days) were well tolerated in participants with Parkinson's disease.

•All treatment-emergent adverse events and treatment-related adverse events were mild in severity, with no serious adverse events, discontinuations, or deaths reported.

•No significant changes in lung functions or respiratory symptoms were observed during the 28 days of treatment or during follow-up.

Pharmacokinetic and Pharmacodynamic Evaluation

•ARV-102 levels in CSF increased in a dose-dependent manner after multiple doses, indicating brain penetration.

•The area under the concentration-time curve (AUC0-24) and the maximum plasma concentration (Cmax) after daily dosing increased with dose with a mean terminal plasma half-life (t1/2) of 68 hours.

•ARV-102 achieved peripheral LRRK2 degradation and dose-dependent degradation of LRRK2 in CSF, with approximately 50% or greater degradation observed at all doses by day 14 and maintained through day 28.

•Endolysosomal and neuroinflammatory pathway proteins that are elevated in LRRK2-related Parkinson's disease (e.g., CD68, GPNMB) were reduced with ARV-102.

•Pharmacology and changes in peripheral biomarkers in patients with Parkinson's disease were consistent with observations in healthy volunteers dosed with ARV-102.

Based on the data, the Company plans to continue investigation of ARV-102 in neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction. Pending regulatory feedback, the Company intends to initiate a Phase 1b clinical

trial in progressive supranuclear palsy in the second quarter of 2026, with the potential to initiate a registrational trial in late 2026, while it continues to evaluate development options for ARV-102 in Parkinson’s disease.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number						Description of Exhibit
99.1						Press Release, dated March 18, 2026
104						Cover Page Interactive Data File (formatted as Inline XBRL)

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the potential of ARV-102; the Company's plans to continue investigation of ARV-102 in neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction; and the Company's intention, pending regulatory feedback, to initiate a Phase 1b clinical trial in progressive supranuclear palsy in the second quarter of 2026, with the potential to initiate a registrational trial in late 2026, while it continues to evaluate development options for ARV-102 in Parkinson’s disease. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company’s belief in the potential of its product candidates, strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words "believe," "intends," "plans," "potential,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes as a result of various risks and uncertainties, including the important factors discussed the important factors discussed in the “Risk Factors” sections contained in the Company’s quarterly and annual reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this Current Report on Form 8-K reflect the Company’s current views with respect to future events, and the Company assumes no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ARVINAS, INC.
Date: March 18, 2026			By:			/s/ Jared Freedberg
						Jared Freedberg General Counsel

Exhibit 99.1 Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days – ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – ARV-102 was well tolerated across all dose levels following 28 days of once-daily dosing – – Data support further development of ARV-102 in additional neurodegenerative diseases characterized by lysosomal dysfunction, including progressive supranuclear palsy, a rapidly progressing and devastating tauopathy – – Data presented during an oral session at the Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders Conference – NEW HAVEN, Conn., March 18, 2026 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today presented data from a Phase 1 clinical trial of ARV-102, an investigational PROteolysis TArgeting Chimera (PROTAC) degrader designed to specifically target and degrade leucine-rich repeat kinase 2 (LRRK2). In the trial, ARV-102 demonstrated approximately 50% or greater reduction of LRRK2 in cerebrospinal fluid (CSF) at all doses by day 14 and maintained the reduction through day 28 in patients with Parkinson’s disease (PD). The Company targeted a 50% reduction based on data showing that patients with PD have a two-fold elevation of LRRK2. Results from the single-center, randomized, double-blind, placebo-controlled, multiple dose (MD) cohort of the Phase 1 clinical trial were shared in an oral presentation at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark. The MD cohort of the Phase 1 clinical trial conducted in patients with PD evaluated ARV-102 oral doses ranging from 20 mg to 80 mg daily for 28 days. Key findings from the trial showed: • ARV-102 exposure in CSF increased in a dose-dependent manner after multiple doses, indicating brain penetration. • ARV-102 achieved approximately 50% or greater LRRK2 reduction in CSF at all doses by day 14 and maintained the reduction through day 28, indicating substantial central LRRK2 protein degradation. • Treatment resulted in reduction of LRRK2 variant and expression-dependent endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB) previously shown to be elevated in neurodegenerative diseases like PD and progressive supranuclear palsy (PSP). • ARV-102 was generally safe and well tolerated with no serious adverse events (SAEs) reported after multiple doses. ARV-102 is an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and specifically target and degrade LRRK2. While LRRK2 is primarily known for its role in PD, emerging evidence suggests that it also plays a role in tauopathies, including PSP, and that LRRK2 dysfunction may contribute to the development and progression of both diseases.

“These data represent exciting progress in the Parkinson’s disease treatment landscape,” said Andrew Siderowf, M.D., Chair of the Parkinson Study Group. “Importantly, ARV-102’s reduction of LRRK2 protein levels and other key biomarkers in patients with Parkinson’s disease suggests that PROTACs may offer a path for future treatment approaches. I look forward to following the continued advancement of ARV-102 and what it could bring for patients." “We are pleased to see compelling and consistent data that reinforce the continued development of ARV-102 as a potential treatment for neurodegenerative diseases like Parkinson’s disease and progressive supranuclear palsy that profoundly impact millions of patients and their families worldwide,” said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer of Arvinas. “To our knowledge, this level of biomarker modulation has not previously been demonstrated by LRRK2 inhibitors, and we believe these data serve as the first of its kind. There is strong evidence that lysosomal dysfunction driven by increased LRRK2 in patients with PSP leads to significant declines in function over one year. Building on these results, and pending regulatory feedback, we intend to initiate a Phase 1b clinical trial in PSP in the second quarter of 2026, with the potential to initiate a registrational trial in late 2026, while we continue evaluating development options for ARV-102 in Parkinson’s disease.” Data presented at AD/PD™ 2026 The ARV-102 Phase 1 clinical trial is designed to assess the safety, pharmacokinetics, and pharmacodynamics of orally administered ARV-102 in patients with PD. Data presented are from the MD cohort of the single-center, randomized, double-blind, placebo-controlled trial. In the MD cohort, patients were randomized to either placebo or multiple oral doses of ARV-102 (20 mg, 40 mg, or 80 mg) for 28 days with follow-up at day 42. Safety Profile • Multiple oral doses of ARV-102 (20 mg, 40 mg, or 80 mg once daily for 28 days) were well tolerated in participants with PD. • All treatment-emergent adverse events and treatment-related adverse events were mild in severity, with no SAEs, discontinuations, or deaths reported. • No significant changes in lung functions or respiratory symptoms were observed during the 28 days of treatment or during follow-up. Pharmacokinetic and Pharmacodynamic Evaluation • ARV-102 levels in CSF increased in a dose-dependent manner after multiple doses, indicating brain penetration. • The area under the concentration-time curve (AUC0-24) and the maximum plasma concentration (Cmax) after daily dosing increased with dose with a mean terminal plasma half-life (t1/2) of 68 hours. • ARV-102 achieved peripheral LRRK2 degradation and dose-dependent degradation of LRRK2 in CSF, with approximately 50% or greater degradation observed at all doses by day 14 and maintained through day 28. • Endolysosomal and neuroinflammatory pathway proteins that are elevated in LRRK2- related PD (e.g., CD68, GPNMB) were reduced with ARV-102. • Pharmacology and changes in peripheral biomarkers in patients with PD were consistent with observations in healthy volunteers dosed with ARV-102.

Based on the positive outcomes of the Phase 1 clinical trial, Arvinas plans to continue investigation of ARV-102 in neurodegenerative diseases associated with LRRK2 and endolysosomal dysfunction. Additional detail on the ARV-102 data presentation at AD/PD™ 2026 follows below: Presentation Title: Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV- 102, a PROTAC LRRK2 Degrader, in Participants with Parkinson’s Disease Session Title: Modulating Neuroinflammation, Α-Synuclein, LRRK2, and Dopaminergic Repair: Early Human Data Session Type: Symposium Session Location: Hall 180-181 Date: March 18, 2026 Lecture Time: 3:30-3:45 PM CET About ARV-102 ARV-102 is an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and specifically target and degrade leucine-rich repeat kinase 2 (LRRK2), a large, multidomain scaffolding kinase with GTPase activity. Increased activity and overexpression of LRRK2 have been implicated in the pathogenesis of neurological diseases, including Parkinson’s disease and progressive supranuclear palsy (PSP). ARV-102 is currently being evaluated in a Phase 1 clinical trial in patients with Parkinson’s disease and Arvinas plans to initiate a Phase 1b clinical trial with ARV-102 in patients with PSP, pending regulatory feedback, in the second quarter of 2026. About Parkinson’s Disease Parkinson’s disease is a progressive brain disease that damages dopamine-producing neurons, leading to progression of symptoms including motor-related symptoms like tremors and limb stiffness, as well as non-motor symptoms including depression, sleep disorders, cognitive decline, and more. LRRK2 activity is abnormally increased in Parkinson’s—and experimental studies strongly suggest that blocking LRRK2 may be neuroprotective. About Progressive Supranuclear Palsy Progressive supranuclear palsy (PSP) is a rare, rapidly progressing neurodegenerative disease that affects brain cells that control balance and coordination, eye movement, speech, swallowing, and thinking. Symptoms may start as early as a patient’s 40s. PSP is characterized by widespread tau pathology. LRRK2 influences tau pathology by directly modifying it and indirectly by disrupting cellular processes (actin, mitochondria, endocytosis) crucial for tau’s normal function and clearance, promoting its toxic accumulation and spread. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative diseases; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic, colorectal, and non-small cell lung cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV- 027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-102, including its degradation of leucine-rich repeat kinase 2 (“LRRK2”), and potential future benefit to patients; the potential of PROteolysis TArgeting Chimeras; Arvinas’ belief that the data presented related to the level of biomarker modulation has not previously been demonstrated by LRRK2 inhibitors and serves as the first of its kind; Arvinas’ plans with respect to ARV-102, including its development and, pending regulatory feedback, the initiation of a Phase 1b clinical trial of ARV-102 in patients with progressive supranuclear palsy, and the initiation of a registrational trial, and the timings thereof; Arvinas’ potential development plans with respect to ARV-102 in Parkinson’s disease; and whether LRRK2 dysfunction contributes to the development and progression Parkinson’s disease and progressive supranuclear palsy. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, development plans, future operations, prospects, plans and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words “ability,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “goal,” “potential,” “whether,” “will,” “would,” “could,” “reliance,” “should,” “look forward,” “seek,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-102, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof, including with respect to ARV-102; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-

looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release. Contacts: Investors: Jeff Boyle +1 (347) 247-5089 Jeff.Boyle@arvinas.com Media: Kirsten Owens +1 (203) 584-0307 Kirsten.Owens@arvinas.com

FAQ

What did Arvinas (ARVN) report about its ARV-102 Phase 1 trial?

Arvinas reported positive Phase 1 data for ARV-102 in Parkinson’s disease. Once-daily oral dosing for 28 days was well tolerated and achieved about 50% or greater LRRK2 reduction in cerebrospinal fluid at all doses, with supportive biomarker and pharmacokinetic findings.

How safe was ARV-102 in the Arvinas (ARVN) Phase 1 Parkinson’s study?

ARV-102 showed a favorable safety profile over 28 days of dosing. All treatment-emergent and treatment-related adverse events were mild, with no serious adverse events, no discontinuations, no deaths, and no significant changes in lung function or respiratory symptoms during treatment or follow-up.

What level of LRRK2 degradation did ARV-102 achieve in the Arvinas (ARVN) trial?

ARV-102 achieved approximately 50% or greater LRRK2 reduction in cerebrospinal fluid at all tested doses by day 14. This reduction was maintained through day 28, indicating substantial central LRRK2 protein degradation and consistent pharmacodynamic target engagement across dose levels.

What doses of ARV-102 were tested in the Arvinas (ARVN) Phase 1 multiple-dose cohort?

The multiple-dose cohort evaluated oral ARV-102 at 20 mg, 40 mg, and 80 mg once daily for 28 days. Patients with Parkinson’s disease were randomized to placebo or these active doses, with follow-up at day 42 to assess safety, pharmacokinetics, and pharmacodynamics.

What are Arvinas’ (ARVN) next development plans for ARV-102?

Arvinas plans to continue investigating ARV-102 in LRRK2- and endolysosomal dysfunction–associated neurodegenerative diseases. Pending regulatory feedback, it intends to start a Phase 1b trial in progressive supranuclear palsy in the second quarter of 2026, with potential initiation of a registrational trial in late 2026.

How did ARV-102 affect biomarkers in the Arvinas (ARVN) Phase 1 trial?

ARV-102 reduced endolysosomal and neuroinflammatory pathway proteins, including CD68 and GPNMB, which are elevated in LRRK2-related Parkinson’s disease. Pharmacology and peripheral biomarker changes in patients with Parkinson’s disease were consistent with observations in healthy volunteers previously dosed with ARV-102.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 15.8 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.9 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 13.3 KB